u-card-img-1
News
Back-to-back publications in Nature

Inhibition of netrin to sensibilize cancer to chemotherapy and immunotherapies: from bench to bedside  

Fundamental and translational studies showing that blockade of netrin with NP137 decreased resistance to anti-cancer treatments by inhibiting the EMT, providing strong scientific rational to the on-going combination clinical trial with NP137.

Learn more
u-card-img-1
News
Publication dans Nature Communications

Vers un diagnostic plus fiable de la maladie d’Alzheimer chez le patient  

L’équipe de Bernard Hanseeuw a identifié une piste vers un diagnostic d’Alzheimer fiable du vivant de la personne, alors qu’à ce jour, seule une autopsie permet de distinguer cette maladie des autres pathologies neuro-dégénératives.  

Learn more
u-card-img-1
News
Call WELBIO 2023

Upcoming opening of the 2023 call for « WELBIO Investigator Programme »  

The 2023 call for "WELBIO Investigator programmes" for fundamental research in the life sciences leading to applications in all fields of (bio)technology will open on 12 September 2023.

Learn more
u-card-img-1
News
WEL-T 2022

Results of the 1st WEL-T call  

14  strategic research programmes in the fields of engineering sciences, chemistry and physics have been selected.  The aim?  To translate breakthrough innovation into applications that promote sustainable transition. 

Learn more
u-card-img-1
News

2022 Annual report  

The year 2022 marked a turning point for our institute with the creation of its new technology department (WEL-T) and a growing societal and economic impact in health (WELBIO).

Learn more
u-card-img-1
News

Philippe Denoël appointed President of the Board of Directors  

Congratulations to Philippe Denoël, Head of Vaccines External R&D at GSK, succeeding to Jean Stéphenne to the role of President of the Governing Board of the WEL Research Institute.  

Learn more
u-card-img-1
News
Publication in Nature

An innovative approach that could improve the efficacy of cancer immunotherapy  

Benoit Van den Eynde's team discovered a new fundamental mechanism, using molecules previously used to treat hypertension, which could help the immune system to fight cancer cells more effectively.

Learn more
u-card-img-1
News
Publication in Nature Cardiovascular Research

Treatment of vascular malformation in utero  

From bench to bedside: How an understanding of the mechanisms of vascular development in Miikka Vikkula's lab led to the prenatal treatment of a foetus suffering from a lymphatic malformation by Dr Laurence Boon's team.

Learn more
u-card-img-1
News
Publication in Nature Communications

Elucidating how mutations in calreticulin induce blood cancer  

For 20 years, Stefan Constantinescu's team has been trying to establish the molecular basis of certain blood cancers (myeloproliferative neoplasms) with several discoveries to their credit.

Learn more
u-card-img-1
News
Publication in J Cachexia Sarcopenia Muscle

Altered hepatic AHR signaling in cancer cachexia impacts liver metabolism  

Laure Bindels and her team showed that altered hepatic AHR receptor signalling could promote liver disorders in cancer cachexia, a syndrome that induces weight loss, muscle wasting and immune deficiency.

Learn more
u-card-img-1
News
Publication in Microbiome

Influence of the gut microbiota on eating behaviour  

Amandine Everard's team demonstrated a causal link between the intestinal microbiota, and more precisely a phenolic metabolite produced by it, and compulsive eating behaviours.

Learn more
u-card-img-1
News
Publication in J Control Release

Oral formulation with lipid nanoparticles : an alternative to injections?  

Ana Beloqui and her team developed an oral formulation, based on lipid nanoparticles, of drugs usually administered by subcutaneous injection in the treatment of non-alcoholic fatty liver disease.

Learn more

Share this page